EGFR and Miyoshi myopathy: To further investigate the role of HB-EGF–EGFR signaling in MM, we repeated the in vitro functional assays with pharmacological blocking of EGFR by erlotinib, which specifically inhibits the receptor’s tyrosine kinase.